Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto

Picard Medical, Inc. is set to showcase its advancements in mechanical circulatory support at the ISHLT 2026 Annual Meeting in Toronto, where Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster titled “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure.” This presentation will detail the ongoing development of a next-generation fully implantable total artificial heart platform, highlighting its potential to address the critical needs of patients with end-stage heart failure.

The significance of this development lies in its potential to transform treatment options for patients suffering from biventricular heart failure. The SynCardia Total Artificial Heart (STAH) is already the only FDA- and Health Canada-approved artificial heart, with over 2,100 implants performed globally. The ongoing innovations aim to enhance the device’s functionality and patient outcomes, aligning with the broader goals of improving life expectancy and healthspan in individuals with severe cardiac conditions.

This participation in ISHLT 2026 not only reinforces Picard Medical’s commitment to advancing mechanical circulatory support technologies but also signals a shift in the research landscape towards more integrated solutions for heart failure management. As the field moves towards personalized and innovative therapies, the insights gained from this event could expedite drug development timelines and foster collaborations that enhance patient care strategies in cardiology.

Source: globenewswire.com